| Pharmaceutical Information |
| Drug Name |
Umeclidinium bromide |
| Drug ID |
BADD_D02315 |
| Description |
Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). It is available as a once-daily inhalation monotherapy or as a fixed-dose combination product with the long-acting beta2-agonist vilanterol. COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less than 80%. By blocking the M3 muscarinic receptor which is highly expressed in airway smooth muscle of the lungs, umeclidinium inhibits the binding of acetylcholine and thereby opens up the airways by preventing bronchoconstriction. Its use has been shown to provide clinically significant, sustained improvements in lung function. |
| Indications and Usage |
Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). |
| Marketing Status |
approved |
| ATC Code |
R03BB07 |
| DrugBank ID |
DB09076
|
| KEGG ID |
D10181
|
| MeSH ID |
C573971
|
| PubChem ID |
11519069
|
| TTD Drug ID |
D09ZOQ
|
| NDC Product Code |
64918-1918; 64918-1920; 52482-012; 58175-0626; 47848-055; 59057-011; 59057-012; 64567-0030 |
| UNII |
7AN603V4JV
|
| Synonyms |
GSK573719 | umeclidinium |
|
| Chemical Information |
| Molecular Formula |
C29H34BrNO2 |
| CAS Registry Number |
869113-09-7 |
| SMILES |
C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5.[Br-] |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
